Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas - Wikidata - wikimedia - TriplyDB

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

http://www.wikidata.org/entity/Q28285708

about

Microtubule-binding agents: a dynamic field of cancer therapeutics.Ixabepilone for the treatment of solid tumors: a review of clinical data Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.Novel microtubule-targeting agents - the epothilones.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas The epothilones: new therapeutic agents for castration-resistant prostate cancer.Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors Bortezomib in mantle cell lymphoma.Ixabepilone for the treatment of taxane-refractory breast cancer.Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.Epothilones in breast cancer: current status and future directions.A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer.The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.Ixabepilone: a new active chemotherapy in the treatment of breast cancer.The epothilones: how pharmacology relates to clinical utility.Dose-toxicity models in oncology.Epothilones in the treatment of ovarian cancer.Global experience with ixabepilone in breast cancer.Ixabepilone for the treatment of breast cancer.Ixabepilone for the treatment of endometrial cancer.Azaepothilone B and its derivatives: a patent review.Macrolactam analogues of macrolide natural products.Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin.Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

P2860

Q27690249-C53F5FB6-BCD0-49BC-90D2-EC4954180ACB Q28271570-888A3C9A-F409-48A6-8EC1-2DCB53CBBFE4 Q30433670-3C188286-4FDA-45C7-9AB1-EF7249DFCC17 Q33380465-7DC6E1F4-F001-4574-9F66-6B9CA4AC0A2A Q33400047-99424421-389B-4016-AD60-F10CD2E460A2 Q34180965-A71346F8-1764-4C95-BB5A-3811709BCEF9 Q34266295-98525308-CE81-4561-851A-CE1FD1A7E968 Q34611212-82B79F8F-94CC-402A-8DD4-9217453C6773 Q34611801-716BC302-E1C8-4F08-BE6B-3EE18ED7C4F7 Q34788890-07777B4D-CAAC-4F8F-B074-40AA8BE51882 Q35096335-8860E03E-1249-4EBD-9C81-999713A5D1BA Q35584399-9449378B-4888-4450-8192-7BD057E07E6F Q35884220-AD66D798-F2C5-4FE2-9FD9-CF3733CC7B9B Q35997562-E518B873-390F-43B7-BBF6-8D8E75ECDB2B Q36714374-D85B3925-8200-412C-8EBD-7949C389043A Q36988082-C568B4DD-A759-4C83-851E-E7B053E9C365 Q37104791-D86DBF33-6514-4928-A854-6E9A4EE631DB Q37136989-C24DC04E-F592-42B1-8352-A24007AAC8D8 Q37179381-B64DB734-76AA-4F93-B1CC-91B110BFF1FF Q37236419-74A65EB2-C107-4DB4-9481-93B5689C4D4C Q37242676-CB6D2172-4CE3-41FE-8585-45DFF0C4B5A7 Q37262792-4BDA1F88-BD11-4BB4-AA62-B63899143166 Q37290709-3842187A-449F-4BBD-8020-D5A1CED074DA Q37356274-57A1514F-6770-422E-8AF2-7A68B78E3936 Q37378233-AB934E66-C6B1-45D7-95C3-3D010C97443B Q37401833-787E2DB3-FB3D-4D8C-99F4-23D2576EFAF0 Q37543912-7767F7B6-D1CD-4736-932D-7D01E4CBA5D5 Q37829437-8F8AF18B-DF09-483A-8C63-26BD7E53199A Q37861204-A1701D6E-FEFF-4891-911B-1A6CE015D218 Q37873462-960A9E35-5472-48B0-B146-5A7046C91CB3 Q37876407-8D799227-4306-404E-B32E-8F1487BB309B Q38763500-80811AF7-4610-41ED-B12E-C45076658052 Q38860410-2E9F8E01-B19F-43D5-917A-04BB66FBED92 Q38998257-F75AF409-8BB4-4381-8A49-15D282A07567 Q47568290-F7615374-25D2-49C1-B3F1-F2CBD8A624CE Q49787954-4E27726E-24A4-46D5-B70A-25F4124EC603 Q57244875-CEEC9E71-68B1-4360-BC28-E85C120A44F1

P2860

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

http://www.wikidata.org/entity/Q28285708

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@ast

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@en

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@nl

type

label

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@ast

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@en

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@nl

prefLabel

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@ast

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@en

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@nl

P1433

Q28285708-222B051D-15FF-4A90-9ECB-5277846D88FF

P1476

Q28285708-409B9AF7-8A42-419D-9EBB-814036F3E9CF

P2093

Q28285708-33B660F1-204E-4A26-8866-79B2E3A4FAB2

Q28285708-3CE8688A-5438-46C9-A0AF-E1A6B388C4BA

Q28285708-575F1B1A-09F8-4F60-8C42-37A0FD3F6534

Q28285708-6F7136B8-CC65-4EA5-A00B-6AB5DD40C9D2

Q28285708-7DB0B331-E011-44A1-8373-DA6B005A3C2D

Q28285708-ABEA18F7-0093-48CE-AD5C-3453FB92CB30

Q28285708-AC9BDC92-E895-4332-B4E8-CE4D4E40A5BA

Q28285708-CF09CABA-762F-4C42-A8E6-3700CCCADF9E

Q28285708-E0FD5F60-1B7C-47E0-B06E-D77AB4120FD0

Q28285708-F5FED27B-E020-4186-B68D-709167814FAB

P304

Q28285708-42E72A9D-390D-4EE9-A3CA-6D4F5CA27752

P31

Q28285708-B89283AA-AFD2-450C-8C60-D83868F54E07

P356

Q28285708-1DD7AF3D-CC70-4301-9482-068FE11E7342

P407

Q28285708-D68B1A72-2687-4E29-9F89-248BE3B0D35C

P433

Q28285708-44AF664F-FADB-46F2-9189-A24D317BE622

P478

Q28285708-52DA0C7E-789C-4485-A123-D66241152990

P577

Q28285708-9ED3EB76-E19E-4191-B6C5-9366370454D8

P698

Q28285708-43F11C81-3148-4EDA-AFD6-40E7D2FA6989

P921

Q28285708-61D6FB3B-8C19-457C-A47B-A946874C8BAB

P356

JCO.2006.08.7304

P1433

Journal of Clinical Oncology

P1476

Phase I study of the novel epo ...... ced solid tumors and lymphomas

@en

P2093

Carol Aghajanian

http://www.w3.org/2001/XMLSchema#string

David R Spriggs

http://www.w3.org/2001/XMLSchema#string

F Anthony Greco

http://www.w3.org/2001/XMLSchema#string

Howard A Burris

http://www.w3.org/2001/XMLSchema#string

Jakob Dupont

http://www.w3.org/2001/XMLSchema#string

Martee L Hensley

http://www.w3.org/2001/XMLSchema#string

Marvin B Cohen

http://www.w3.org/2001/XMLSchema#string

Owen A O'Connor

http://www.w3.org/2001/XMLSchema#string

Paul Sabbatini

http://www.w3.org/2001/XMLSchema#string

Ronald Peck

http://www.w3.org/2001/XMLSchema#string

P304

1082-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.08.7304

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17261851

http://www.w3.org/2001/XMLSchema#string

P921